Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$6.2MCash on Hand
3.8mo Cash Runway
Follow NTHI by emailGet an email when NTHI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NTHI, unsubscribe in one click. Privacy
📣 What NTHI Says Is Next
this year · “For NEO100, our fully enrolled Phase 2a study in recurrent IDH1-mutant high-grade glioma continues progressing toward an anticipated interim data readout later this year.”
Company press release, May 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Clinical trial NeOnc furnished an investor presentation updating clinical development. An additional response in the NEO100 Phase 2a study brings responses to 3 of 24 patients, raising the objective response rate from 8.3% to 12.5% per RANO 2.0. Form 8-K · SEC filing · Press release
Nov 13, 2026 ·
Regulatory CEO Amir Heshmatpour bought 80,000 NeOnc shares on the open market on Nov 5, 6 and 9, 2026, for about $269,082 at roughly $3.36 per share. The company also said FDA granted a Type B End-of-Phase meeting for intranasal NEO100 in recurrent IDH-mutant grade 4 astrocytoma, scheduled for early January 2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Earnings NeOnc reported Q3 2026 net loss of $4.4M, down from $8.6M, and operating expenses of $5.8M, down from $6.9M. Cash was about $6.2M after a $15M offering and $5.8M preferred stock redemption. NEO100 and NEO212 data is set for the SNO meeting on November 13. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
NeOnc Technologies will present data from its intranasal NEO100 and oral NEO212 programs in two posters on November 13, 2026, at the Society for Neuro-Oncology annual meeting in Philadelphia. Form 8-K · SEC filing · Press release
Oct 15, 2026 ·
Leadership Steven Giannotta, M.D. resigned from the board effective October 9, 2026, not over any disagreement with the company. Ali Mohammad Ahmad Alabedin, Group Head of Islamic Banking at First Abu Dhabi Bank, was appointed director, serving until the 2029 annual meeting, with no committee assignments. Form 8-K · SEC filing · Press release
Sep 28, 2026 ·
Regulatory NeOnc will meet with FDA on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting on NEO212, to discuss Phase 2 study design, endpoints, and possible accelerated approval. The meeting does not establish FDA agreement on any trial design or pathway. Form 8-K · SEC filing · Press release
Sep 21, 2026 ·
Restructuring NeOnc redeemed all 6,000 outstanding Series A Convertible Preferred shares for cash at an aggregate stated value of $6.0 million, funded from its recent registered direct offering, and eliminated the preferred designation with no common shares issued. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2026 · Phase 1/2 · Active Trial · Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma Registry primary completion date, not a results date
Dec 2026 · Phase 2 · Recruiting · NEO100 and High-Grade Meningioma Registry primary completion date, not a results date
Feb 2027 · Phase 1/2 · Recruiting · Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Registry primary completion date, not a results date
Jun 2027 · Phase 1 · Recruiting · A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not NTHI's own candidates): Bevacizumab, Carboplatin, Ziv-Aflibercept, Ipilimumab, Nivolumab, Paclitaxel, Pembrolizumab, Regorafenib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NTHI holds $6.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.9M/quarter from operations,
an estimated runway of 3.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:79 · High
Cash runway 4 months +40
Shelf registration (S-3, Apr 2026) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt regarding the Company’s ability to continue as a going concern one year from the issuance date of this Form 10-Q.10-Q, Nov 2026
Share count 28,850,588 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NTHI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NTHI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.